Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors

Blood

Volumn 127, Issue 11, 2016, Pages 1481-1492

  Dulmovits, Brian M ^a,b   Appiah Kubi, Abena O ^a,b   Papoin, Julien ^a   Hale, John ^c   He, Mingzhu ^a   Al Abed, Yousef ^a   Didier, Sebastien ^a   Gould, Michael ^b   Husain Krautter, Sehba ^a   Singh, Sharon A ^b   Chan, Kyle W H ^d   Vlachos, Adrianna ^b   Allen, Steven L ^b,e   Taylor, Naomi ^f   Marambaud, Philippe ^a   An, Xiuli ^c   Gallagher, Patrick G ^g   Mohandas, Narla ^c   Lipton, Jeffrey M ^a,b   Liu, Johnson M ^a,b   Blanc, Lionel ^a,b   more..

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d Biotheryx Inc   (United States)

^e North Shore LIJ Medical Group   (United States)

^f INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HISTONE DEACETYLASE 1; IKAROS TRANSCRIPTION FACTOR; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 1; POMALIDOMIDE; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR SOX6; UNCLASSIFIED DRUG; BCL11A PROTEIN, HUMAN; CARRIER PROTEIN; ERYTHROID KRUPPEL-LIKE FACTOR; HEMOGLOBIN BETA CHAIN; HISTONE DEMETHYLASE; IKZF1 PROTEIN, HUMAN; KDM1A PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEASOME; SMALL INTERFERING RNA; SOX6 PROTEIN, HUMAN; THALIDOMIDE; TRANSCRIPTION FACTOR SOX; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BURST FORMING UNIT E; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; COLONY FORMING UNIT; COLONY FORMING UNIT E; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GENE SILENCING; HEMOGLOBINOPATHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; ADULT; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BLOOD; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSCRIPTION; GENETICS; HEMATOPOIETIC STEM CELL; LENTIVIRINAE; METABOLISM; RNA INTERFERENCE;

ADULT; ANEMIA, SICKLE CELL; BETA-GLOBINS; CARRIER PROTEINS; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; FETAL HEMOGLOBIN; GAMMA-GLOBINS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HISTONE DEMETHYLASES; HUMANS; IKAROS TRANSCRIPTION FACTOR; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LENTIVIRUS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA INTERFERENCE; RNA, SMALL INTERFERING; SOXD TRANSCRIPTION FACTORS; THALIDOMIDE; TRANSCRIPTION, GENETIC;

EID: 84961833440     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-667923     Document Type: Article

References (41)

1. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123(5):615-624.
2. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-4336.
3. Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221-230.
4. Khandros E, Weiss MJ. Protein quality control during erythropoiesis and hemoglobin synthesis. Hematol Oncol Clin North Am. 2010;24(6):1071-1088.
5. Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am. 2010;24(6):1005-1020.
6. Ginzburg Y, Rivella S. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011;118(16):4321-4330.
7. Arlet JB, Ribeil JA, Guillem F, et al. HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia. Nature. 2014;514(7521):242-246.
8. Orkin SH, Higgs DR. Medicine. Sickle cell disease at 100 years. Science. 2010;329(5989):291-292.
9. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018-2031.
10. Sankaran VG, Xu J, Orkin SH. Advances in the understanding of haemoglobin switching. Br J Haematol. 2010;149(2):181-194.
11. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-938.
12. Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood. 2014;124(26):3850-3857, quiz 4004.
13. Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood. 2015;125(17):2597-2604.
14. Lipton JM. Curing sickle cell disease: Mission accomplished? Pediatr Blood Cancer. 2015;62(7):1129-1130.
15. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314-322.
16. Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12(1):42-54.
17. Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013;122(14):2305-2309.
18. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301-305.
19. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblondependent destruction of Ikaros proteins. Science. 2014;343(6168):305-309.
20. Koh KR, Janz M, Mapara MY, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood. 2005;105(10):3833-3840.
21. Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest. 2008;118(1):248-258.
22. Meiler SE, Wade M, Kutlar F, et al. Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood. 2011;118(4):1109-1112.
23. Giarratana MC, Rouard H, Dumont A, et al. Proof of principle for transfusion of in vitro-generated red blood cells. Blood. 2011;118(19):5071-5079.
24. Hu J, Liu J, Xue F, et al. Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. Blood. 2013;121(16):3246-3253.
25. Li J, Hale J, Bhagia P, et al. Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E. Blood. 2014;124(24):3636-3645.
26. Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood. 2012;120(15):2945-2953.
27. Xu J, Bauer DE, Kerenyi MA, et al. Corepressordependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci USA. 2013;110(16):6518-6523.
28. Cui S, Kolodziej KE, Obara N, et al. Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells. Mol Cell Biol. 2011;31(16):3298-3311.
29. Amaya M, Desai M, Gnanapragasam MN, et al. Mi2β-mediated silencing of the fetal γ-globin gene in adult erythroid cells. Blood. 2013;121(17):3493-3501.
30. Katsumura KR, De Vilbiss AW, Pope NJ, Johnson KD, Bresnick EH. Transcriptional mechanisms underlying hemoglobin synthesis. Cold Spring Harb Perspect Med. 2013;3(9):a015412.
31. Xu J, Sankaran VG, Ni M, et al. Transcriptional silencing of gamma-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev. 2010;24(8):783-798.
32. Dijon M, Bardin F, Murati A, Batoz M, Chabannon C, Tonnelle C. The role of Ikaros in human erythroid differentiation. Blood. 2008;111(3):1138-1146.
33. Lopez RA, Schoetz S, De Angelis K, O'Neill D, Bank A. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice. Proc Natl Acad Sci USA. 2002;99(2):602-607.
34. Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore). 2001;80(5):328-344.
35. Papayannopoulou TH, Brice M, Stamatoyannopoulos G. Stimulation of fetal hemoglobin synthesis in bone marrow cultures from adult individuals. Proc Natl Acad Sci USA. 1976;73(6):2033-2037.
36. Papayannopoulou T, Brice M, Stamatoyannopoulos G. Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells. Proc Natl Acad Sci USA. 1977;74(7):2923-2927.
37. Tang DC, Zhu J, Liu W, et al. The hydroxyureainduced small GTP-binding protein SAR modulates gamma-globin gene expression in human erythroid cells. Blood. 2005;106(9):3256-3263.
38. Zhu J, Chin K, Aerbajinai W, Kumkhaek C, Li H, Rodgers GP. Hydroxyurea-inducible SAR1 gene acts through the Giα/JNK/Jun. pathway to regulate γ-globin expression. Blood. 2014;124(7):1146-1156.
39. Li Z, Qiu Y, Personett D, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013;8(8):e71754.
40. Basak A, Hancarova M, Ulirsch JC, et al. BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations. J Clin Invest. 2015;125(6):2363-2368.
41. Funnell AP, Prontera P, Ottaviani V, et al. 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood. 2015;126(1):89-93.